|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bao Y, Wang Z, Liu B, Lu X, Xiong Y, Shi
J, Li P, Chen J, Zhang Z, Chen M, et al: A feed-forward loop
between nuclear translocation of CXCR4 and HIF-1α promotes renal
cell carcinoma metastasis. Oncogene. 38:881–895. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haber T, Jöckel E, Roos FC, Junker K,
Prawitt D, Hampel C, Thüroff JW and Brenner W; German Renal Cell
Tumor Network, : Bone metastasis in renal cell carcinoma is
preprogrammed in the primary tumor and caused by AKT and Integrin
α5 Signaling. J Urol. 194:539–546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Thayele Purayil H, Black JB,
Fetto F, Lynch LD, Masannat JN and Daaka Y: Prostaglandin E2
receptor 4 mediates renal cell carcinoma intravasation and
metastasis. Cancer Lett. 391:50–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Obeng RC, Arnold RS, Ogan K, Master VA,
Pattaras JG, Petros JA and Osunkoya AO: Molecular characteristics
and markers of advanced clear cell renal cell carcinoma: Pitfalls
due to intratumoral heterogeneity and identification of genetic
alterations associated with metastasis. Int J Urol. 27:790–797.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue YJ, Chen SN, Chen WG, Wu GQ, Liao YF,
Xu JB, Tang H, Yang SH, He SY, Luo YF, et al: Cripto-1 expression
in patients with clear cell renal cell carcinoma is associated with
poor disease outcome. J Exp Clin Cancer Res. 38:3782019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasuya G, Tsuji H, Nomiya T, Makishima H,
Haruyama Y, Kobashi G, Ebner DK, Hayashi K, Omatsu T, Kishimoto R,
et al: Updated long-term outcomes after carbon-ion radiotherapy for
primary renal cell carcinoma. Cancer Sci. 109:2873–2880. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Q, Shi J, Yuan F, Wang H, Fu W, Pan
J, Huang Y, Yu J, Yang J and Chen Z: Higher expression of XPF is a
critical factor in intrinsic chemotherapy resistance of human renal
cell carcinoma. Int J Cancer. 139:2827–2837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diamond E, Molina AM, Carbonaro M, Akhtar
NH, Giannakakou P, Tagawa ST and Nanus DM: Cytotoxic chemotherapy
in the treatment of advanced renal cell carcinoma in the era of
targeted therapy. Crit Rev Oncol Hematol. 96:518–526. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rini BI, Battle D, Figlin RA, George DJ,
Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ,
et al: The society for immunotherapy of cancer consensus statement
on immunotherapy for the treatment of advanced renal cell carcinoma
(RCC). J Immunother Cancer. 7:3542019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhindi B, Habermann EB, Mason RJ, Costello
BA, Pagliaro LC, Thompson RH, Leibovich BC and Boorjian SA:
Comparative survival following initial cytoreductive nephrectomy
versus initial targeted therapy for metastatic renal cell
carcinoma. J Urol. 200:528–534. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gershman B, Thompson RH, Boorjian SA,
Lohse CM, Costello BA, Cheville JC and Leibovich BC: Radical versus
partial nephrectomy for cT1 renal cell carcinoma. Eur Urol.
74:825–832. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tabayoyong W, Abouassaly R, Kiechle JE,
Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC,
Zhu H, et al: Variation in surgical margin status by surgical
approach among patients undergoing partial nephrectomy for small
renal masses. J Urol. 194:1548–1553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weiss J, Notohamiprodjo M, Bedke J,
Nikolaou K and Kaufmann S: Imaging response assessment of
immunotherapy in patients with renal cell and urothelial carcinoma.
Curr Opin Urol. 28:35–41. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caliò A, Harada S, Brunelli M, Pedron S,
Segala D, Portillo SC, Magi-Galluzzi C, Netto GJ, Mackinnon AC and
Martignoni G: TFEB rearranged renal cell carcinoma. A
clinicopathologic and molecular study of 13 cases. Tumors harboring
MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations
constantly express PDL1. Mod Pathol. 34:842–850. 2021. View Article : Google Scholar
|
|
19
|
de Velasco G, Culhane AC, Fay AP, Hakimi
AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn
Rathmell W, et al: Molecular subtypes improve prognostic value of
International Metastatic Renal Cell Carcinoma Database Consortium
Prognostic Model. Oncologist. 22:286–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stamatovic SM, Martinez-Revollar G, Hu A,
Choi J, Keep RF and Andjelkovic AV: Decline in Sirtuin-1 expression
and activity plays a critical role in blood-brain barrier
permeability in aging. Neurobiol Dis. 126:105–116. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Islam S, Uehara O, Matsuoka H, Kuramitsu
Y, Adhikari BR, Hiraki D, Toraya S, Jayawardena A, Saito I,
Muthumala M, et al: DNA hypermethylation of sirtuin 1 (SIRT1)
caused by betel quid chewing-a possible predictive biomarker for
malignant transformation. Clin Epigenetics. 12:122020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ming M, Zhao B, Shea C, Shea CR, Shah P,
Qiang L, White SR, Sims DM and He YY: Loss of sirtuin 1 (SIRT1)
disrupts skin barrier integrity and sensitizes mice to epicutaneous
allergen challenge. J Allergy Clin Immunol. 135:936–945.e4. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalous KS, Wynia-Smith SL, Olp MD and
Smith BC: Mechanism of Sirt1 NAD+-dependent protein deacetylase
inhibition by Cysteine S-Nitrosation. J Biol Chem. 291:25398–25410.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chandrasekaran K, Anjaneyulu M, Choi J,
Kumar P, Salimian M, Ho CY and Russell JW: Role of mitochondria in
diabetic peripheral neuropathy: Influencing the NAD-dependent
SIRT1-PGC-1α-TFAM pathway. Int Rev Neurobiol. 145:177–209. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okamoto S, Asgar NF, Yokota S, Saito K and
Minokoshi Y: Role of the α2 subunit of AMP-activated protein kinase
and its nuclear localization in mitochondria and energy
metabolism-related gene expressions in C2C12 cells. Metabolism.
90:52–68. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanazawa I, Takeno A, Tanaka KI, Notsu M
and Sugimoto T: Osteoblast AMP-activated protein kinase regulates
glucose metabolism and bone mass in adult mice. Biochem Biophys Res
Commun. 503:1955–1961. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang S, Wang Y, Luo L, Shi F, Zou J, Lin
H, Ying Y, Luo Y, Zhan Z, Liu P, et al: AMP-activated protein
kinase regulates cancer cell growth and metabolism via nuclear and
mitochondria events. J Cell Mol Med. 23:3951–3961. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou X, Xu S, Maitland-Toolan KA, Sato K,
Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, et al:
SIRT1 regulates hepatocyte lipid metabolism through activating
AMP-activated protein kinase. J Biol Chem. 283:20015–20026. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bae UJ, Park J, Park IW, Chae BM, Oh MR,
Jung SJ, Ryu GS, Chae SW and Park BH:
Epigallocatechin-3-Gallate-Rich Green tea extract ameliorates fatty
liver and weight gain in mice fed a high fat diet by activating the
Sirtuin 1 and AMP activating protein kinase pathway. Am J Chin Med.
46:617–632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shentu TP, He M, Sun X, Zhang J, Zhang F,
Gongol B, Marin TL, Zhang J, Wen L, Wang Y, et al: AMP-Activated
Protein Kinase and Sirtuin 1 Coregulation of cortactin contributes
to endothelial function. Arterioscler Thromb Vasc Biol.
36:2358–2368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chou X, Ding F, Zhang X, Ding X, Gao H and
Wu Q: Sirtuin-1 ameliorates cadmium-induced endoplasmic reticulum
stress and pyroptosis through XBP-1s deacetylation in human renal
tubular epithelial cells. Arch Toxicol. 93:965–986. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo H, Ding H, Tang X, Liang M, Li S,
Zhang J and Cao J: Quercetin induces pro-apoptotic autophagy via
SIRT1/AMPK signaling pathway in human lung cancer cell lines A549
and H1299 in vitro. Thorac Cancer. May 11–2021.(Epub ahead of
print). doi: 10.1111/1759-7714.13925. View Article : Google Scholar
|
|
34
|
Subbaramaiah K, Iyengar NM, Morrow M,
Elemento O, Zhou XK and Dannenberg AJ: Prostaglandin E2
down-regulates sirtuin 1 (SIRT1), leading to elevated levels of
aromatase, providing insights into the obesity-breast cancer
connection. J Biol Chem. 294:361–371. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
George J, Nihal M, Singh CK and Ahmad N:
4′-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor,
inhibits melanoma cell growth through mitochondrial metabolic
reprogramming. Mol Carcinog. 58:1876–1885. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warren AY and Harrison D: WHO/ISUP
classification, grading and pathological staging of renal cell
carcinoma: Standards and controversies. World J Urol. 36:1913–1926.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miranda-Gonçalves V, Lameirinhas A,
Macedo-Silva C, Lobo J, C Dias P, Ferreira V, Henrique R and
Jerónimo C: Lactate increases renal cell carcinoma aggressiveness
through Sirtuin 1-dependent epithelial mesenchymal transition axis
regulation. Cells. 9:10532020. View Article : Google Scholar
|
|
39
|
Jeh SU, Park JJ, Lee JS, Kim DC, Do J, Lee
SW, Choi SM, Hyun JS, Seo DH, Lee C, et al: Differential expression
of the sirtuin family in renal cell carcinoma: Aspects of
carcinogenesis and prognostic significance. Urol Oncol.
35:675.e9–675.e15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Y, Zhu Y, Sheng Y, Xiao J, Xiao Y,
Cheng N, Chai Y, Wu X, Zhang S and Xiang T: SIRT1 downregulated FGB
expression to inhibit RCC tumorigenesis by destabilizing STAT3. Exp
Cell Res. 382:1114662019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feng H, Guo P, Wang J, Xu J, Xie C and Gao
F: Expression of Leptin and Sirtuin-1 is associated with poor
prognosis in patients with osteosarcoma. Pathol Res Pract.
212:319–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yan L, Zhao Q, Liu L, Jin N, Wang S and
Zhan X: Expression of SIRT1 and survivin correlates with poor
prognosis in esophageal squamous cell carcinoma. Medicine
(Baltimore). 99:e216452020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chung SY, Jung YY, Park IA, Kim H, Chung
YR, Kim JY, Park SY, Im SA, Lee KH, Moon HG, et al: Oncogenic role
of SIRT1 associated with tumor invasion, lymph node metastasis, and
poor disease-free survival in triple negative breast cancer. Clin
Exp Metastasis. 33:179–185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dong YJ, Liu N, Xiao Z, Sun T, Wu SH, Sun
WX, Xu ZG and Yuan H: Renal protective effect of sirtuin 1. J
Diabetes Res. 2014:8437862014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Chen J, Sun L and Xu Y: SIRT1
deacetylates KLF4 to activate Claudin-5 transcription in ovarian
cancer cells. J Cell Biochem. 119:2418–2426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Atkins KM, Thomas LL, Barroso-González J,
Thomas L, Auclair S, Yin J, Kang H, Chung JH, Dikeakos JD and
Thomas G: The multifunctional sorting protein PACS-2 regulates
SIRT1-mediated deacetylation of p53 to modulate p21-dependent
cell-cycle arrest. Cell Rep. 8:1545–1557. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Han Y, Luo H, Wang H, Cai J and Zhang YJ:
SIRT1 induces resistance to apoptosis in human granulosa cells by
activating the ERK pathway and inhibiting NF-κB signaling with
anti-inflammatory functions. Apoptosis. 22:1260–1272. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fu H, Song W, Chen X, Guo T, Duan B, Wang
X, Tang Y, Huang L and Zhang C: MiRNA-200a induce cell apoptosis in
renal cell carcinoma by directly targeting SIRT1. Mol Cell Biochem.
437:143–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang LF, Wang XN, Huang CC, Hu L, Xiao YF,
Guan XH, Qian YS, Deng KY and Xin HB: Inhibition of NAMPT
aggravates high fat diet-induced hepatic steatosis in mice through
regulating Sirt1/AMPKα/SREBP1 signaling pathway. Lipids Health Dis.
16:822017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dong HW, Zhang LF and Bao SL: AMPK
regulates energy metabolism through the SIRT1 signaling pathway to
improve myocardial hypertrophy. Eur Rev Med Pharmacol Sci.
22:2757–2766. 2018.PubMed/NCBI
|
|
53
|
Tian L, Cao W, Yue R, Yuan Y, Guo X, Qin
D, Xing J and Wang X: Pretreatment with Tilianin improves
mitochondrial energy metabolism and oxidative stress in rats with
myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha
signaling pathway. J Pharmacol Sci. 139:352–360. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang L, Quan N, Sun W, Chen X, Cates C,
Rousselle T, Zhou X, Zhao X and Li J: Cardiomyocyte-specific
deletion of Sirt1 gene sensitizes myocardium to ischaemia and
reperfusion injury. Cardiovasc Res. 114:805–821. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cao Y, Bojjireddy N, Kim M, Li T, Zhai P,
Nagarajan N, Sadoshima J, Palmiter RD and Tian R: Activation of
γ2-AMPK suppresses ribosome biogenesis and protects against
myocardial ischemia/reperfusion injury. Circ Res. 121:1182–1191.
2017. View Article : Google Scholar : PubMed/NCBI
|
